3 reports

  • interactions involving dendritic cells, osteoblasts, and soluble factors such as IL-12 and cytoprotectant erythropoietin.
  • JAN 09, 2014: NEUMEDICINES TO FEATURE HEMAMAX STUDY RESULTS IN PRESENTATION AT BIOTECH SHOWCASE CONFERENCE

In the same study, ## consecutive days of treatment with Neupogen® (filgrastim or granulocyte colonystimulating factor [G-CSF]) did not provide any survival benefit versus control.

  • Interleukin
  • Therapy
  • United States
  • Product Initiative
  • Neumedicines Inc.
  • Pipeline by Amgen Inc., H1 2016

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Digestive System Disorder
  • Interleukin
  • United States
  • World
  • Product Initiative

THE COMPANY' S KEY PRODUCTS INCLUDE NEULASTA (PEGFILGRASTIM); NEUPOGEN (FILGRASTIM) INDICATED FOR CANCER TREATMENT; ENBREL (ENTANERCEPT) FOR TREATING RHEUMATOID ARTHRITIS; EPOGEN (ERYTHROPOIETIC STIMULATING AGENTS); ARANESP (DARBEPOETIN ALFA) TO TREAT ANEMIA ASSOCIATED WITH CHRONIC KIDN

  • Interleukin
  • Therapy
  • United States
  • World
  • Product Initiative